- Home
- ACET vs PHUN Comparison
ACET vs PHUN Comparison
Compare ACET & PHUN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ACET | PHUN |
|---|---|---|
| Founded | 1947 | 2009 |
| Country | United States | United States |
| Employees | N/A | 29 |
| Industry | Biotechnology: Pharmaceutical Preparations | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 69.6M | 35.9M |
| IPO Year | 2017 | 2016 |
Fundamental Metrics
Financial Performance| Metric | ACET | PHUN |
|---|---|---|
| Price | $7.24 | $1.80 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 2 |
| Target Price | ★ $65.33 | $7.25 |
| AVG Volume (30 Days) | 182.8K | ★ 203.2K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 59.82 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $30,883,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $95.95 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 15.57 |
| 52 Week Low | $0.45 | $1.56 |
| 52 Week High | $9.05 | $3.88 |
Technical Indicators
Market Signals| Indicator | ACET | PHUN |
|---|---|---|
| Relative Strength Index (RSI) | 53.18 | 49.31 |
| Support Level | $0.62 | $1.79 |
| Resistance Level | $8.46 | $2.04 |
| Average True Range (ATR) | 0.52 | 0.10 |
| MACD | -0.07 | 0.01 |
| Stochastic Oscillator | 73.50 | 44.16 |
Price Performance
Historical ComparisonAbout ACET Adicet Bio Inc.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.
About PHUN Phunware Inc.
Phunware Inc is a software company. It is a cloud platform for mobile that provides companies with the products, solutions, and data and services necessary to engage, manage and monetize its mobile application audiences. It derives maximum revenue from United States. The company has two reportable segments: Software subscriptions and services; and Advertising. It derives maximum revenue from Software subscriptions and services.